Staff Association representatives are in regular contact with CSIRO Executives responsible for the organisation’s coronavirus (COVID-19) workforce response.
We believe that the safety of CSIRO staff should remain paramount and that financial disadvantage should be minismised for all employees – permanent, fixed-term, casual, contractor or labour-hire – as a direct result of management decisions or directions in response to COVID-19.
This is a special resource for CSIRO Staff Association members. If you’re not yet a member of the union, email us for more information about membership.
Following the most recent formal negotiation meeting, all bargaining parties have arranged for an Enterprise Agreement (EA) proposal to be submitted to the Australian Public Service Commission (APSC) for assessment.
For now, formal negotiation meetings have ceased, but will reconvene following the outcome of the APSC assessment and the direction provided to Staff Association negotiators by members.
The Staff Association will enter into a comprehensive consultation period, including workplace meetings by video conference and an online poll.
The union representing CSIRO staff has welcomed news that a multi-million dollar upgrade of the Australian Animal Health Laboratory – to be renamed Australian Centre for Disease Preparedness – will proceed with an additional funding boost to support the facility’s research to develop a COVID-19 vaccine.
CSIRO will spend $220 million to refurbish and upgrade the biosecurity centre – home to the only Physical Containment (PC) 4 laboratory in the southern hemisphere – funded partly by the planned sale of the organisation’s research farm located in Ginninderra on the outskirts of Canberra.
The Federal Government has also announced an additional $10 million to support CSIRO’s research into the novel coronavirus; which this week began animal testing into two potential vaccines in conjunction with the Coalition for Epidemic Preparedness Innovations (CEPI), an international public-private partnership which marshals global research to respond to disease epidemics.
CSIRO has commenced the first stage of testing potential vaccines for COVID-19. The testing, expected to take three months, is underway at the Australian Animal Health Laboratory in Geelong.
To prepare for disease outbreaks, last year CSIRO partnered with the Coalition for Epidemic Preparedness Innovations (CEPI), a global group that aims to derail epidemics by speeding up the development of vaccines.
In January, CEPI engaged CSIRO to start working on the virus SARS CoV-2, which causes the disease COVID-19. In consultation with the World Health Organisation, CEPI has identified vaccine candidates from The University of Oxford (UK) and Inovio Pharmaceuticals Inc. (US) to undergo the first pre-clinical trials at CSIRO, with further candidates likely to follow.